首页 | 本学科首页   官方微博 | 高级检索  
     


Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas,resistant to androgen-deprivation therapy
Authors:Laura D Locati  Federica Perrone  Barbara Cortelazzi  Martina Imbimbo  Paolo Bossi  Paolo Potepan  Enrico Civelli  Gaetana Rinaldi  Pasquale Quattrone  Lisa Licitra  Silvana Pilotti
Affiliation:1.Head and Neck Medical Oncology Unit; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy;2.Laboratory of Experimental Molecular Pathology; Pathology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy;3.Radiology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy;4.Medical Oncology; Azienda Policlinico Universitario Paolo Giaccone; Palermo, Italy;5.Pathology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy
Abstract:
Androgen-deprivation therapy (ADT) has been reported to be active in androgen receptor (AR)-expressing, relapsed/metastatic (RM), salivary gland cancers (SGCs). Abiraterone, an inhibitor of androgen synthesis, has recently been approved as a second-line treatment in hormone-resistant (HR) prostate cancer (PCa) patients. Two patients with AR-positive HR-RM adenocarcinoma, NOS of the salivary glands have been treated with abiraterone. This is the first time that this agent has been reported to be active in tumors other than HRPCa. Immunohistochemical analysis showed overexpression of EGFR, HER2, and HER3 in both untreated primary tumors. Sequencing analysis revealed a TP53 non-functional mutation in one case and a PIK3CA-activating mutation in the other. In conclusion, second line activity of ADT in AR-expressing, adenocarcinoma, NOS of salivary glands further strengthens the pathogenic and therapeutic role of AR signaling in AR-positive SGCs.
Keywords:androgen receptor   androgen deprivation therapy   HER3   PIK3CA   TP53   abiraterone   salivary gland cancers
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号